NCT04460820View on ClinicalTrials.gov

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 4, 2019

Primary Completion Date

December 23, 2019

Study Completion Date

December 23, 2019

Conditions
Bioequivalence
Interventions
DRUG

Doxorubicin Hydrochloride Liposome Injection

50mg/m2,IV on Day 1 of each cycle

Trial Locations (1)

050000

Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT04460820 - A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection | Biotech Hunter | Biotech Hunter